// App-Quantinova.ai

AB1196 : A STUDY REVIEWING THE ASSOCIATED FACTORS AND COST-EVALUATION OF SWITCHING BACK TO ORIGINATOR-ETANERCEPT FROM ITS BIOSIMILAR AMONG PATIENTS WITH RHEUMATIC DISORDERS AT A TERTIARY CARE CENTRE IN UNITED KINGDOM

Researchers

Presenter

  • S. S. C. Silva

Principal Investigators

  • B. Mahesh

  • T. Rajakulenthiran

  • R. Singh

  • R. Amarasena

Medical Centers

  • The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom

  • University of Melbourne, Population and Global Health Unit, Melbourne, Australia

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved